Genmab Announces HuMax CD32b Pre Clinical Program

Genmab A/S (OMX: GEN) announced today a new pre-clinical antibody program called HuMax-CD32b(TM). This fully human IgG1,k antibody targets the CD32b receptor found on immune cells and hematological tumors. HuMax-CD32b may have therapeutic potential in the treatment of B-cell chronic lymphocytic leukemia, small lymphocytic lymphoma, Burkitt’s lymphoma, follicular lymphoma and diffuse large B-cell lymphoma. The […]

Cephalon Submits New Drug Application For TREANDA For The Treatment Of Patients With Relapsed Indolent Non Hodgkin’s Lymphoma

Cephalon, Inc. (Nasdaq: CEPH) announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of TREANDA(R) (bendamustine HCl) for Injection for the treatment of patients with indolent B-cell non-Hodgkin’s lymphoma (NHL) who have progressed during or following treatment with rituximab or a rituximab-containing regimen. According […]

Interim Safety Analysis Supports Continuation Of Allos Therapeutics’ Pivotal Phase 2 PROPEL Trial Of PDX In Patients With Peripheral T-cell Lymphoma

Allos Therapeutics, Inc. (Nasdaq: ALTH) announced that an independent Data Monitoring Committee (DMC) has completed the pre-specified 65-patient safety review of data from the Company’s pivotal Phase 2 PROPEL trial of PDX (pralatrexate) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), and has recommended that the trial continue per the protocol. This interim […]

Kiadis Pharma Reports Successful End Of Phase II Meeting With FDA For Reviroc

Kiadis Pharma announced that it has successfully completed an End of Phase II meeting for Reviroc with the U.S. Food and Drug Administration (FDA). Reviroc is under development for elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. The FDA agreed that the data from the completed […]

Firefly Genes Allow Testing Of New Therapy Against Lymphoma

Researchers here have figured out a way to use a firefly gene to let them see just how effective a new drug combination actually is against some forms of cancer and their serious complications. The new study looked at ATLL, adult T-cell lymphoma and leukemia, a form of cancer where it is particularly hard to […]

Chemotherapy And Radiotherapy Should Be Standard Treatment For Localised Hodgkin’s Lymphoma

A combination of chemotherapy and radiotherapy, rather than radiotherapy alone, should now be considered standard treatment for all patients with localised Hodgkin’s lymphoma where the tumour is situated above the diaphragm, according to the results of a randomized controlled trial. Furthermore, the trial results suggest that radiotherapy need only target areas directly involved in the […]

OXiGENE’s ZYBRESTATTM Reported To Have Anti-Leukemic Effects In Preclinical Studies Published In Blood

OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported that its lead product candidate, ZYBRESTATTM (combretastatin A4 phosphate / CA4P), demonstrated anti-leukemic effects in preclinical studies published online and ahead of print on November 16, 2007 on the website of the journal BLOOD. The […]

Key Gene Link To Acute Myeloid Leukemia Found

A gene called N-Myc leads a double life in certain white blood cells, helping to trigger a cancer called acute myeloid leukemia (AML) under some conditions while triggering apoptosis, or cell suicide, under other conditions, according to results of a mouse study done by investigators at St. Jude Children’s Research Hospital. “This discovery gives researchers […]

Trials For Oral Therapy Revlimid (Lenalidomide) Show Unprecedented Overall Survival And Response Rates In Blood Cancer, Multiple Myeloma

The results of two pivotal Phase III trials, published in this week’s prestigious New England Journal of Medicine, showed that patients with the blood cancer multiple myeloma who were treated with REVLIMID┬« (lenalidomide) had among the longest median survival rates, the longest time until the disease progressed and the highest response (remission) rate ever reported […]

The International Myeloma Foundation Says REVLIMID(R) Extends Survival With Positive Implications For A Wide Range Of Blood Cancers

The International Myeloma Foundation (IMF) – supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians – said findings from two large, international clinical trials are good news for myeloma patients, especially patients with active myeloma despite previous treatments. The newly published data demonstrate that with REVLIMID┬«, an oral cancer […]